Testing effectiveness (Phase 2)Study completedNCT02544633
What this trial is testing
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
Who this might be right for
Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. 68